Non-regulatory-arkiv | Page 12 of 15 | Affibody Medical AB

Affibody Medical Investor Relations

Categories:

Navigation:

Non-Regulatory

February 15, 2013

Year-End Report 2012

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...

Non-Regulatory

November 1, 2012

Interim Report – January to Sept 2012

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...

Non-Regulatory

August 7, 2012

Interim Report – January to June 2012

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...

Non-Regulatory

July 10, 2012

Sobi enters Research Collaboration with Affibody within the IL-1 field

Solna, July 10, 2012. Sobi has signed a research collaboration and option agreement with the Swedish biotech company Affibody AB for the discovery and development of novel treatments for...

Non-Regulatory

June 2, 2012

GE Healthcare and Affibody AB to Collaborate on Her2 specific PET Imaging Agent for Breast and Gastric Cancer

ST Giles Chalfont, UK, & Solna, Sweden, June 02, 2012. GE Healthcare signed an agreement with Affibody AB (“Affibody”) to collaborate on the development of a Her2-targeted PET imaging...

Non-Regulatory

April 27, 2012

Interim Report – January to March 2012

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...

Non-Regulatory

February 10, 2012

Year-End Report 2011

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...

Non-Regulatory

February 2, 2012

Affibody AB and Creative Antibiotics AB enter collaboration to develop targeted antibiotics.

Solna, February 2, 2012. Affibody AB today signed an agreement with Creative Antibiotics AB with the aim of developing pharmaceutical candidates targeting gram negative bacteria.

Non-Regulatory

December 20, 2011

Affibody AB and Nuclisome AB to Develop Cancer Therapeutics

Solna, Sweden, December 20, 2011. Affibody AB today announced a collaboration agreement with Nuclisome AB with the aim of developing new cancer therapeutics.